<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03007524</url>
  </required_header>
  <id_info>
    <org_study_id>KY20160608-02</org_study_id>
    <nct_id>NCT03007524</nct_id>
  </id_info>
  <brief_title>Early Vascular Healing in Acute Coronary Syndrome Patients With Different Doses of Rosuvastatin</brief_title>
  <acronym>CROWN-1</acronym>
  <official_title>A Randomized Comparison of Low-dose Versus High-dose Rosuvastatin on Optical Coherence Tomography Based Early Vascular Healing for Patients With Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing First Hospital, Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized trial comparing different doses of rosuvastatin in patients&#xD;
      with acute coronary syndrome post drug-eluting stents implantation. Through the study, the&#xD;
      investigators aim to evaluate the effects of high dose rosuvastatin calcium on &quot;target&#xD;
      vessel&quot; endothelialization and &quot;non-target vessel&quot; plaque stability. Moreover, the&#xD;
      investigators may provide mechanically evidence of clinical application of high dose&#xD;
      rosuvastatin in patients with acute coronary syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, randomized controlled clinical trial comparing different&#xD;
      doses of rosuvastatin in patients with acute coronary syndrome post drug-eluting stents&#xD;
      implantation. In total, the investigators plan to recruit 80 patients with acute coronary&#xD;
      syndrome (but no acute ST-segment elevation myocardial infarction) participating in the&#xD;
      study. After signing informed consent form, the patients will be randomly assigned into high&#xD;
      dose rosuvastatin and low dose rosuvastatin groups (40 cases in each group) by a computer&#xD;
      generated random sequence table on a ratio of 1:1. Patients in the high-dose group will be&#xD;
      prescribed rosuvastatin calcium of 20mg/d at least 6 months post index procedure, while&#xD;
      patients in low dose group will have rosuvastatin calcium of 10mg/d, also at least 6 months.&#xD;
      Additionally, all patients will receive dual antiplatelet therapy (oral aspirin 100mg qd,&#xD;
      clopidogrel 75mg qd or ticagrelor 90 mg bid). Clinical follow up (telephone or out-patient&#xD;
      follow-up) will be scheduled at 30 days, 6 months, 1 year, 2 years and 3 years. Optical&#xD;
      coherence tomography examinations will be performed at 6 months. Neointimal hyperplasia,&#xD;
      stent strut coverage and thin cap fibroatheroma are primary observational parameters.&#xD;
      Multi-slices CT are optional pre-/post-procedure and at 3 years follow-up. All clinical data&#xD;
      will be collected and managed by statistical center, clinical endpoint adjudication&#xD;
      committee. All imaging modalities data will be collected and analysed by an independent&#xD;
      imaging core laboratory.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of covered struts</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean/Minimal stent diameter</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/Minimal stent area</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/Minimal stent volume</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/Minimal lumen diameter</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/Minimal lumen area</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/Minimal lumen volume</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/Minimal vessel diameter</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/Minimal vessel area</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/Minimal vessel volume</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/Minimal thickness of stent strut coverage</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thin cap fibroatheroma(TCFA)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cap thickness of thin cap fibroatheroma(TCFA)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neointimal Hyperplasia area</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neointimal Hyperplasia volume</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incomplete strut apposition</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device-oriented composite endpoint</measure>
    <time_frame>1 and 6 months, 1, 2, 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>1 and 6 months, 1, 2, 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal myocardial infarction</measure>
    <time_frame>1 and 6 months, 1, 2, 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All revascularization</measure>
    <time_frame>1 and 6 months, 1, 2, 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target lesion revascularization</measure>
    <time_frame>1 and 6 months, 1, 2, 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target vessel revascularization</measure>
    <time_frame>1 and 6 months, 1, 2, 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis</measure>
    <time_frame>1 and 6 months, 1, 2, 3 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Lipid levels</measure>
    <time_frame>Baseline，6 months</time_frame>
    <description>Total cholesterol（TC）,low density lipoprotein(LDL),high density lipoprotein(HDL),LDL/HDL,triglyceride</description>
  </other_outcome>
  <other_outcome>
    <measure>Biological index</measure>
    <time_frame>Baseline，6 months</time_frame>
    <description>High sensitivity c-reactive protein（hs-CRP）,Pentraxin-3(PTX-3),Vascular cell adhesion molecule-1(VCAM-1),Matrix metallopeptidase-9(MMP-9)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>High dose rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20mg/d quaque nocte(qN), at least 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10mg/d quaque nocte（qN）, at least 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose Rosuvastatin</intervention_name>
    <description>20mg/d qN, at least 6 months</description>
    <arm_group_label>High dose rosuvastatin</arm_group_label>
    <other_name>Rosuvastatin Calcium</other_name>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose Rosuvastatin</intervention_name>
    <description>10mg/d qN, at least 6 months</description>
    <arm_group_label>Low dose rosuvastatin</arm_group_label>
    <other_name>Rosuvastatin Calcium</other_name>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 to 75 years male or non-pregnant female;&#xD;
&#xD;
          2. Clinical evidence of unstable angina or non ST segment elevation myocardial infarction&#xD;
             (NSTEMI);&#xD;
&#xD;
          3. The patient has up to two de novo native coronary lesions in different epicardial&#xD;
             vessels;&#xD;
&#xD;
          4. Target lesion diameter stenosis ≧70%(visually estimated);&#xD;
&#xD;
          5. Each target lesion must be treated with maximal 2 stents (except the bailout&#xD;
             stenting);&#xD;
&#xD;
          6. Low density lipoprotein (LDL) higher than 100mg/dL or lower than 100mg/dL but have&#xD;
             taken statin drugs less than 1 month before enrolled;&#xD;
&#xD;
          7. Patient is an acceptable candidate for emergency coronary artery bypass grafting;&#xD;
&#xD;
          8. The patient is able to understand the aim of this study, provide voluntarily written&#xD;
             informed content and agree to the follow-up visits including angiographic、multislice&#xD;
             spiral computed tomography(MSCT) and optical coherence tomography(OCT) examinations;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any acute myocardial infarction within the past 1 months; myocardial enzyme not back&#xD;
             to normal after myocardial infarction;&#xD;
&#xD;
          2. Chronic total occlusive lesion, severe left main coronary artery disease, orifice&#xD;
             lesion, 3-vessel disease, bifurcation lesions (with side branch diameter greater than&#xD;
             2 mm, orifice diameter stenosis greater than or equal to 50%, or side branch need to&#xD;
             be protected by guidewire or balloon), OCT imaging is not suitable for the lesion site&#xD;
             or OCT imaging is incomplete, Target lesion located in previous venous or arterial&#xD;
             bypass grafts, Target lesion has visible thrombus, intercurrent infection, or other&#xD;
             inflammatory diseases.;&#xD;
&#xD;
          3. Heavily calcified lesions, severely tortuous lesions, lesions cannot be well&#xD;
             pre-dilated and/or unsuitable of the stent crossover/expansion;&#xD;
&#xD;
          4. In-stent restenosis lesions;&#xD;
&#xD;
          5. Prior percutaneous coronary intervention(PCI) within the past 1 year; plan to possibly&#xD;
             have re-intervention within 1 year post index-procedure; previous PCI more than 1 year&#xD;
             at the target vessel;&#xD;
&#xD;
          6. Instability of hemodynamic or respiratory cycle, such as cardiogenic shock, Heart&#xD;
             failure with severe symptoms (over New York Heart Association III(NYHA III)) or left&#xD;
             ventricular ejection fraction less than 40% (UCG or left ventricle radiography);&#xD;
&#xD;
          7. Known renal insufficiency (e.g, Glomerular filtration rate(eGFR) &lt;60 ml/kg/m2 or serum&#xD;
             creatinine level of &gt;2.5 mg/dL, or subject on dialysis);&#xD;
&#xD;
          8. History of bleeding tendency, active peptic ulcer and cerebral hemorrhage or retinal&#xD;
             hemorrhage, and a half years history of stroke, antiplatelet agents and anticoagulants&#xD;
             therapy contraindications to anticoagulation in patients;&#xD;
&#xD;
          9. Patients have been used statins and other lipid-lowering drug treatment more than 1&#xD;
             month before enrolled,patients allergy to rosuvastatin or use rosuvastatin with&#xD;
             contraindications,patients allergy to aspirin, clopidogrel or ticagrelor, heparin,&#xD;
             contrast agent, polymer, zotarolimus and metal;&#xD;
&#xD;
         10. Life expectancy &lt;6 months;&#xD;
&#xD;
         11. Currently participating in an investigational drug or another device study that has&#xD;
             not completed the primary endpoint;&#xD;
&#xD;
         12. Unable or unwilling to comply with the protocol or not expected to complete the study&#xD;
             period, including its follow-up requirements;&#xD;
&#xD;
         13. The patient is a recipient of a heart transplant;&#xD;
&#xD;
         14. Unstable arrhythmia, such as high risk ventricular contraction, ventricular&#xD;
             arrhythmia;&#xD;
&#xD;
         15. With the need of chemotherapy in 30 days due to malignancy;&#xD;
&#xD;
         16. Patients with immune suppression or autoimmune diseases planning to have or currently&#xD;
             receive immunosuppressive therapy;&#xD;
&#xD;
         17. Patients planning to have or currently receive long-term anticoagulation therapy;&#xD;
&#xD;
         18. Patients may receive surgery within 6 months post index-procedure in which needs to&#xD;
             stop aspirin, clopidogrel or ticagrelor;&#xD;
&#xD;
         19. Neutropenia (&lt;1000 neutrophils/mm3), Thrombocytopenia (&lt;100,000 platelets/mm3),&#xD;
             Confirmed or suspected diagnosis of liver diseases;&#xD;
&#xD;
         20. Patients with diffuse peripheral vascular disease which precludes 6 French unit(6F)&#xD;
             sheath insertion;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yao-Jun Zhang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ze-Ning Jin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Anzhen Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fei Ye, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Song Lin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bo Xu, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Fu Wai Hospital, Beijing, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yong-Xiang Zhu, MSc</last_name>
    <email>zhuyongxiang_njmu@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nanjing First Hospital, Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhang Yao-Jun, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Zhu Yong-Xiang, MSC</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Morice MC, Serruys PW, Barragan P, Bode C, Van Es GA, Stoll HP, Snead D, Mauri L, Cutlip DE, Sousa E. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol. 2007 Oct 2;50(14):1299-304. doi: 10.1016/j.jacc.2007.06.029. Epub 2007 Sep 17.</citation>
    <PMID>17903626</PMID>
  </reference>
  <reference>
    <citation>Grech ED. ABC of interventional cardiology: percutaneous coronary intervention. I: history and development. BMJ. 2003 May 17;326(7398):1080-2. doi: 10.1136/bmj.326.7398.1080. No abstract available.</citation>
    <PMID>12750213</PMID>
  </reference>
  <reference>
    <citation>Gottsauner-Wolf M, Zasmeta G, Hornykewycz S, Nikfardjam M, Stepan E, Wexberg P, Zorn G, Glogar D, Probst P, Maurer G, Huber K. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J. 2000 Jul;21(14):1152-8. doi: 10.1053/euhj.1999.1987.</citation>
    <PMID>10924298</PMID>
  </reference>
  <reference>
    <citation>Walter DH, Fichtlscherer S, Britten MB, Rosin P, Auch-Schwelk W, Schachinger V, Zeiher AM. Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol. 2001 Dec;38(7):2006-12. doi: 10.1016/s0735-1097(01)01662-x.</citation>
    <PMID>11738308</PMID>
  </reference>
  <reference>
    <citation>Losordo DW, Isner JM, Diaz-Sandoval LJ. Endothelial recovery: the next target in restenosis prevention. Circulation. 2003 Jun 3;107(21):2635-7. doi: 10.1161/01.CIR.0000071083.31270.C3. No abstract available.</citation>
    <PMID>12782613</PMID>
  </reference>
  <reference>
    <citation>Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation. 1998 Jul 21;98(3):224-33. doi: 10.1161/01.cir.98.3.224.</citation>
    <PMID>9697822</PMID>
  </reference>
  <reference>
    <citation>Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010 Mar 9;121(9):1069-77. doi: 10.1161/CIRCULATIONAHA.109.906479. Epub 2010 Feb 22.</citation>
    <PMID>20176986</PMID>
  </reference>
  <reference>
    <citation>Cholesterol Treatment Trialists' (CTT) Collaborators; Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008 Jan 12;371(9607):117-25. doi: 10.1016/S0140-6736(08)60104-X.</citation>
    <PMID>18191683</PMID>
  </reference>
  <reference>
    <citation>Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8.</citation>
    <PMID>21067804</PMID>
  </reference>
  <reference>
    <citation>Cholesterol Treatment Trialists' (CTT) Collaborators; Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012 Aug 11;380(9841):581-90. doi: 10.1016/S0140-6736(12)60367-5. Epub 2012 May 17.</citation>
    <PMID>22607822</PMID>
  </reference>
  <reference>
    <citation>Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009 Jun 30;338:b2376. doi: 10.1136/bmj.b2376.</citation>
    <PMID>19567909</PMID>
  </reference>
  <reference>
    <citation>Hou W, Lv J, Perkovic V, Yang L, Zhao N, Jardine MJ, Cass A, Zhang H, Wang H. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J. 2013 Jun;34(24):1807-17. doi: 10.1093/eurheartj/eht065. Epub 2013 Mar 6.</citation>
    <PMID>23470492</PMID>
  </reference>
  <reference>
    <citation>Ray KK, Cannon CP, Ganz P. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials? Am J Cardiol. 2006 Dec 4;98(11A):18P-25P. doi: 10.1016/j.amjcard.2006.09.016. Epub 2006 Sep 29.</citation>
    <PMID>17126675</PMID>
  </reference>
  <reference>
    <citation>Almuti K, Rimawi R, Spevack D, Ostfeld RJ. Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol. 2006 Apr 28;109(1):7-15. doi: 10.1016/j.ijcard.2005.05.056. Epub 2005 Jul 28.</citation>
    <PMID>16054715</PMID>
  </reference>
  <reference>
    <citation>Liu T, Li L, Korantzopoulos P, Liu E, Li G. Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol. 2008 May 23;126(2):160-70. doi: 10.1016/j.ijcard.2007.07.137. Epub 2007 Nov 26.</citation>
    <PMID>18031847</PMID>
  </reference>
  <reference>
    <citation>Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford RM. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest. 1993 Oct;92(4):1866-74. doi: 10.1172/JCI116778.</citation>
    <PMID>7691889</PMID>
  </reference>
  <reference>
    <citation>Karalis IK, Bergheanu SC, Wolterbeek R, Dallinga-Thie GM, Hattori H, van Tol A, Liem AH, Wouter Jukema J. Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters. Curr Med Res Opin. 2010 Oct;26(10):2301-13. doi: 10.1185/03007995.2010.509264.</citation>
    <PMID>20731529</PMID>
  </reference>
  <reference>
    <citation>Kleemann R, Princen HM, Emeis JJ, Jukema JW, Fontijn RD, Horrevoets AJ, Kooistra T, Havekes LM. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation. 2003 Sep 16;108(11):1368-74. doi: 10.1161/01.CIR.0000086460.55494.AF. Epub 2003 Aug 25.</citation>
    <PMID>12939225</PMID>
  </reference>
  <reference>
    <citation>Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, Walsh K, Isner JM, Asahara T. HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. J Clin Invest. 2001 Aug;108(3):399-405. doi: 10.1172/JCI13131.</citation>
    <PMID>11489933</PMID>
  </reference>
  <reference>
    <citation>Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol. 1997 Nov 1;30(5):1212-7. doi: 10.1016/s0735-1097(97)00324-0.</citation>
    <PMID>9350917</PMID>
  </reference>
  <reference>
    <citation>Mizukoshi M, Imanishi T, Tanaka A, Kubo T, Liu Y, Takarada S, Kitabata H, Tanimoto T, Komukai K, Ishibashi K, Akasaka T. Clinical classification and plaque morphology determined by optical coherence tomography in unstable angina pectoris. Am J Cardiol. 2010 Aug 1;106(3):323-8. doi: 10.1016/j.amjcard.2010.03.027.</citation>
    <PMID>20643240</PMID>
  </reference>
  <reference>
    <citation>Akasaka T, Kubo T, Mizukoshi M, Tanaka A, Kitabata H, Tanimoto T, Imanishi T. Pathophysiology of acute coronary syndrome assessed by optical coherence tomography. J Cardiol. 2010 Jul;56(1):8-14. doi: 10.1016/j.jjcc.2010.05.005. Epub 2010 Jun 15.</citation>
    <PMID>20554431</PMID>
  </reference>
  <reference>
    <citation>Bezerra HG, Costa MA, Guagliumi G, Rollins AM, Simon DI. Intracoronary optical coherence tomography: a comprehensive review clinical and research applications. JACC Cardiovasc Interv. 2009 Nov;2(11):1035-46. doi: 10.1016/j.jcin.2009.06.019.</citation>
    <PMID>19926041</PMID>
  </reference>
  <reference>
    <citation>Kubo T, Imanishi T, Kashiwagi M, Ikejima H, Tsujioka H, Kuroi A, Ishibashi K, Komukai K, Tanimoto T, Ino Y, Kitabata H, Takarada S, Tanaka A, Mizukoshi M, Akasaka T. Multiple coronary lesion instability in patients with acute myocardial infarction as determined by optical coherence tomography. Am J Cardiol. 2010 Feb 1;105(3):318-22. doi: 10.1016/j.amjcard.2009.09.032. Epub 2009 Dec 22.</citation>
    <PMID>20102942</PMID>
  </reference>
  <reference>
    <citation>Kubo T, Imanishi T, Takarada S, Kuroi A, Ueno S, Yamano T, Tanimoto T, Matsuo Y, Masho T, Kitabata H, Tsuda K, Tomobuchi Y, Akasaka T. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J Am Coll Cardiol. 2007 Sep 4;50(10):933-9. doi: 10.1016/j.jacc.2007.04.082. Epub 2007 Aug 20.</citation>
    <PMID>17765119</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>July 12, 2016</study_first_submitted>
  <study_first_submitted_qc>December 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2017</study_first_posted>
  <last_update_submitted>February 19, 2017</last_update_submitted>
  <last_update_submitted_qc>February 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing First Hospital, Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Yao-Jun Zhang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>rosuvastatin</keyword>
  <keyword>optical coherence tomography</keyword>
  <keyword>acute coronary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03007524
org study id: KY20160608-02
nct id: NCT03007524
lead sponsor: 
has dmc: Yes
This is a prospective, randomized trial comparing different doses of rosuvastatin in patients
      with acute coronary syndrome post drug-eluting stents implantation. Through the study, the
      investigators aim to evaluate the effects of high dose rosuvastatin calcium on "target
      vessel" endothelialization and "non-target vessel" plaque stability. Moreover, the
      investigators may provide mechanically evidence of clinical application of high dose
      rosuvastatin in patients with acute coronary syndrome.
This is a prospective, multicenter, randomized controlled clinical trial comparing different
      doses of rosuvastatin in patients with acute coronary syndrome post drug-eluting stents
      implantation. In total, the investigators plan to recruit 80 patients with acute coronary
      syndrome (but no acute ST-segment elevation myocardial infarction) participating in the
      study. After signing informed consent form, the patients will be randomly assigned into high
      dose rosuvastatin and low dose rosuvastatin groups (40 cases in each group) by a computer
      generated random sequence table on a ratio of 1:1. Patients in the high-dose group will be
      prescribed rosuvastatin calcium of 20mg/d at least 6 months post index procedure, while
      patients in low dose group will have rosuvastatin calcium of 10mg/d, also at least 6 months.
      Additionally, all patients will receive dual antiplatelet therapy (oral aspirin 100mg qd,
      clopidogrel 75mg qd or ticagrelor 90 mg bid). Clinical follow up (telephone or out-patient
      follow-up) will be scheduled at 30 days, 6 months, 1 year, 2 years and 3 years. Optical
      coherence tomography examinations will be performed at 6 months. Neointimal hyperplasia,
      stent strut coverage and thin cap fibroatheroma are primary observational parameters.
      Multi-slices CT are optional pre-/post-procedure and at 3 years follow-up. All clinical data
      will be collected and managed by statistical center, clinical endpoint adjudication
      committee. All imaging modalities data will be collected and analysed by an independent
      imaging core laboratory.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Single (Outcomes Assessor)
measure: Proportion of covered struts
time frame: 6 months
measure: Mean/Minimal stent diameter
time frame: 6 months
measure: Mean/Minimal stent area
time frame: 6 months
measure: Mean/Minimal stent volume
time frame: 6 months
measure: Mean/Minimal lumen diameter
time frame: 6 months
measure: Mean/Minimal lumen area
time frame: 6 months
measure: Mean/Minimal lumen volume
time frame: 6 months
measure: Mean/Minimal vessel diameter
time frame: 6 months
measure: Mean/Minimal vessel area
time frame: 6 months
measure: Mean/Minimal vessel volume
time frame: 6 months
measure: Mean/Minimal thickness of stent strut coverage
time frame: 6 months
measure: thin cap fibroatheroma(TCFA)
time frame: 6 months
measure: Cap thickness of thin cap fibroatheroma(TCFA)
time frame: 6 months
measure: Neointimal Hyperplasia area
time frame: 6 months
measure: Neointimal Hyperplasia volume
time frame: 6 months
measure: Incomplete strut apposition
time frame: 6 months
measure: Device-oriented composite endpoint
time frame: 1 and 6 months, 1, 2, 3 years
measure: Cardiac death
time frame: 1 and 6 months, 1, 2, 3 years
measure: Non-fatal myocardial infarction
time frame: 1 and 6 months, 1, 2, 3 years
measure: All revascularization
time frame: 1 and 6 months, 1, 2, 3 years
measure: target lesion revascularization
time frame: 1 and 6 months, 1, 2, 3 years
measure: target vessel revascularization
time frame: 1 and 6 months, 1, 2, 3 years
measure: stent thrombosis
time frame: 1 and 6 months, 1, 2, 3 years
measure: Lipid levels
time frame: Baseline，6 months
description: Total cholesterol（TC）,low density lipoprotein(LDL),high density lipoprotein(HDL),LDL/HDL,triglyceride
measure: Biological index
time frame: Baseline，6 months
description: High sensitivity c-reactive protein（hs-CRP）,Pentraxin-3(PTX-3),Vascular cell adhesion molecule-1(VCAM-1),Matrix metallopeptidase-9(MMP-9)
arm group label: High dose rosuvastatin
arm group type: Experimental
description: 20mg/d quaque nocte(qN), at least 6 months
arm group label: Low dose rosuvastatin
arm group type: Active Comparator
description: 10mg/d quaque nocte（qN）, at least 6 months
intervention type: Drug
intervention name: High dose Rosuvastatin
description: 20mg/d qN, at least 6 months
arm group label: High dose rosuvastatin
other name: Rosuvastatin Calcium
other name: Crestor
intervention type: Drug
intervention name: Low dose Rosuvastatin
description: 10mg/d qN, at least 6 months
arm group label: Low dose rosuvastatin
other name: Rosuvastatin Calcium
other name: Crestor
criteria: 
gender: All
minimum age: 18 Years
maximum age: 75 Years
healthy volunteers: No
last name: Yao-Jun Zhang, PhD
role: Principal Investigator
affiliation: The First Affiliated Hospital with Nanjing Medical University
last name: Ze-Ning Jin, PhD
role: Principal Investigator
affiliation: Beijing Anzhen Hospital
last name: Fei Ye, PhD
role: Principal Investigator
affiliation: The First Affiliated Hospital with Nanjing Medical University
last name: Song Lin, PhD
role: Principal Investigator
affiliation: The First Affiliated Hospital with Nanjing Medical University
last name: Bo Xu, MSc
role: Study Director
affiliation: Fu Wai Hospital, Beijing, China
last name: Yong-Xiang Zhu, MSc
email: zhuyongxiang_njmu@163.com
facility: 
status: Recruiting
contact: 
contact backup: 
country: China
citation: Morice MC, Serruys PW, Barragan P, Bode C, Van Es GA, Stoll HP, Snead D, Mauri L, Cutlip DE, Sousa E. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol. 2007 Oct 2;50(14):1299-304. doi: 10.1016/j.jacc.2007.06.029. Epub 2007 Sep 17.
PMID: 17903626
citation: Grech ED. ABC of interventional cardiology: percutaneous coronary intervention. I: history and development. BMJ. 2003 May 17;326(7398):1080-2. doi: 10.1136/bmj.326.7398.1080. No abstract available.
PMID: 12750213
citation: Gottsauner-Wolf M, Zasmeta G, Hornykewycz S, Nikfardjam M, Stepan E, Wexberg P, Zorn G, Glogar D, Probst P, Maurer G, Huber K. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J. 2000 Jul;21(14):1152-8. doi: 10.1053/euhj.1999.1987.
PMID: 10924298
citation: Walter DH, Fichtlscherer S, Britten MB, Rosin P, Auch-Schwelk W, Schachinger V, Zeiher AM. Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol. 2001 Dec;38(7):2006-12. doi: 10.1016/s0735-1097(01)01662-x.
PMID: 11738308
citation: Losordo DW, Isner JM, Diaz-Sandoval LJ. Endothelial recovery: the next target in restenosis prevention. Circulation. 2003 Jun 3;107(21):2635-7. doi: 10.1161/01.CIR.0000071083.31270.C3. No abstract available.
PMID: 12782613
citation: Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation. 1998 Jul 21;98(3):224-33. doi: 10.1161/01.cir.98.3.224.
PMID: 9697822
citation: Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010 Mar 9;121(9):1069-77. doi: 10.1161/CIRCULATIONAHA.109.906479. Epub 2010 Feb 22.
PMID: 20176986
citation: Cholesterol Treatment Trialists' (CTT) Collaborators; Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008 Jan 12;371(9607):117-25. doi: 10.1016/S0140-6736(08)60104-X.
PMID: 18191683
citation: Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8.
PMID: 21067804
citation: Cholesterol Treatment Trialists' (CTT) Collaborators; Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012 Aug 11;380(9841):581-90. doi: 10.1016/S0140-6736(12)60367-5. Epub 2012 May 17.
PMID: 22607822
citation: Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009 Jun 30;338:b2376. doi: 10.1136/bmj.b2376.
PMID: 19567909
citation: Hou W, Lv J, Perkovic V, Yang L, Zhao N, Jardine MJ, Cass A, Zhang H, Wang H. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J. 2013 Jun;34(24):1807-17. doi: 10.1093/eurheartj/eht065. Epub 2013 Mar 6.
PMID: 23470492
citation: Ray KK, Cannon CP, Ganz P. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials? Am J Cardiol. 2006 Dec 4;98(11A):18P-25P. doi: 10.1016/j.amjcard.2006.09.016. Epub 2006 Sep 29.
PMID: 17126675
citation: Almuti K, Rimawi R, Spevack D, Ostfeld RJ. Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol. 2006 Apr 28;109(1):7-15. doi: 10.1016/j.ijcard.2005.05.056. Epub 2005 Jul 28.
PMID: 16054715
citation: Liu T, Li L, Korantzopoulos P, Liu E, Li G. Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol. 2008 May 23;126(2):160-70. doi: 10.1016/j.ijcard.2007.07.137. Epub 2007 Nov 26.
PMID: 18031847
citation: Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford RM. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest. 1993 Oct;92(4):1866-74. doi: 10.1172/JCI116778.
PMID: 7691889
citation: Karalis IK, Bergheanu SC, Wolterbeek R, Dallinga-Thie GM, Hattori H, van Tol A, Liem AH, Wouter Jukema J. Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters. Curr Med Res Opin. 2010 Oct;26(10):2301-13. doi: 10.1185/03007995.2010.509264.
PMID: 20731529
citation: Kleemann R, Princen HM, Emeis JJ, Jukema JW, Fontijn RD, Horrevoets AJ, Kooistra T, Havekes LM. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation. 2003 Sep 16;108(11):1368-74. doi: 10.1161/01.CIR.0000086460.55494.AF. Epub 2003 Aug 25.
PMID: 12939225
citation: Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, Walsh K, Isner JM, Asahara T. HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. J Clin Invest. 2001 Aug;108(3):399-405. doi: 10.1172/JCI13131.
PMID: 11489933
citation: Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol. 1997 Nov 1;30(5):1212-7. doi: 10.1016/s0735-1097(97)00324-0.
PMID: 9350917
citation: Mizukoshi M, Imanishi T, Tanaka A, Kubo T, Liu Y, Takarada S, Kitabata H, Tanimoto T, Komukai K, Ishibashi K, Akasaka T. Clinical classification and plaque morphology determined by optical coherence tomography in unstable angina pectoris. Am J Cardiol. 2010 Aug 1;106(3):323-8. doi: 10.1016/j.amjcard.2010.03.027.
PMID: 20643240
citation: Akasaka T, Kubo T, Mizukoshi M, Tanaka A, Kitabata H, Tanimoto T, Imanishi T. Pathophysiology of acute coronary syndrome assessed by optical coherence tomography. J Cardiol. 2010 Jul;56(1):8-14. doi: 10.1016/j.jjcc.2010.05.005. Epub 2010 Jun 15.
PMID: 20554431
citation: Bezerra HG, Costa MA, Guagliumi G, Rollins AM, Simon DI. Intracoronary optical coherence tomography: a comprehensive review clinical and research applications. JACC Cardiovasc Interv. 2009 Nov;2(11):1035-46. doi: 10.1016/j.jcin.2009.06.019.
PMID: 19926041
citation: Kubo T, Imanishi T, Kashiwagi M, Ikejima H, Tsujioka H, Kuroi A, Ishibashi K, Komukai K, Tanimoto T, Ino Y, Kitabata H, Takarada S, Tanaka A, Mizukoshi M, Akasaka T. Multiple coronary lesion instability in patients with acute myocardial infarction as determined by optical coherence tomography. Am J Cardiol. 2010 Feb 1;105(3):318-22. doi: 10.1016/j.amjcard.2009.09.032. Epub 2009 Dec 22.
PMID: 20102942
citation: Kubo T, Imanishi T, Takarada S, Kuroi A, Ueno S, Yamano T, Tanimoto T, Matsuo Y, Masho T, Kitabata H, Tsuda K, Tomobuchi Y, Akasaka T. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J Am Coll Cardiol. 2007 Sep 4;50(10):933-9. doi: 10.1016/j.jacc.2007.04.082. Epub 2007 Aug 20.
PMID: 17765119
responsible party type: Principal Investigator
investigator affiliation: Nanjing First Hospital, Nanjing Medical University
investigator full name: Yao-Jun Zhang
investigator title: Principal Investigator
mesh term: Acute Coronary Syndrome
mesh term: Syndrome
mesh term: Calcium, Dietary
mesh term: Rosuvastatin Calcium
mesh term: Calcium
sharing ipd: Undecided